The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects
Status:
Completed
Trial end date:
2012-03-15
Target enrollment:
Participant gender:
Summary
This is a First Time in Human (FTIH) study for the sodium channel inhibitor, GSK2339345. The
study is split into two parts. Part A will assess the safety and tolerability of the new
drug. Part B will assess safety and tolerability as well as the effect of GSK2339345 on
induced cough.